INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 427m ago
HOUSE PTR27m ago
SEC 13F27m ago
ROBINHOOD CHAIN26m ago
SEC FORM 4/Grant or awardVerified data

Kolbeck Roland Wilhelm reported ACRS

Chief Scientific Officer · Aclaris Therapeutics, Inc. · Aclaris Therapeutics, Inc. — Restricted Stock Units

Side
A
Value
—
Shares
95.7K
Price
—
Executed
Feb 2, 2026
Disclosed
Feb 6, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 2 executedFeb 6, 2026 disclosed

ACRS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
15/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+6 / 15

    Disclosed 4 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ACRS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    HW
    Hall Jesse WayneChief Medical Officer
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    36.4K sh
    		May 1, 2026May 5, 2026
    traded May 1, 2026
    		+4dSEC FORM 4

    Evidence

    21
    HW
    Hall Jesse WayneChief Medical Officer
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    36.4K sh
    		May 1, 2026May 5, 2026
    traded May 1, 2026
    		+4dSEC FORM 4

    Evidence

    21
    HW
    Hall Jesse WayneChief Medical Officer
    ACRSAclaris Therapeutics, Inc.
    Tax withholding
    		F$41K
    9,330 sh
    		May 1, 2026May 5, 2026
    traded May 1, 2026
    		+4dSEC FORM 4

    Evidence

    15
    HW
    Hall Jesse WayneChief Medical Officer
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    98.1K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    15
    KW
    Kolbeck Roland WilhelmChief Scientific Officer
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    334.9K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    15
    HW
    Hall Jesse WayneChief Medical Officer
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    343.3K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    15
    DM
    Davis Hugh M.Director, President and COO
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    96.1K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    15
    DM
    Davis Hugh M.Director, President and COO
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    336.3K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    15
    BK
    Balthaser KevinChief Financial Officer
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    99.1K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    15
    BK
    Balthaser KevinChief Financial Officer
    ACRSAclaris Therapeutics, Inc.
    Grant or award
    		A—
    346.8K sh
    		Feb 2, 2026Feb 6, 2026
    traded Feb 2, 2026
    		+4dSEC FORM 4

    Evidence

    21
    BK
    Balthaser KevinChief Financial Officer
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    22.0K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DM
    Davis Hugh M.Director, President and COO
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    18.7K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    13
    BK
    Balthaser KevinChief Financial Officer
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    22.0K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BK
    Balthaser KevinChief Financial Officer
    ACRSAclaris Therapeutics, Inc.
    Tax withholding
    		F$22K
    6,449 sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DM
    Davis Hugh M.Director, President and COO
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    18.7K sh
    		Feb 3, 2026Feb 5, 2026
    traded Feb 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    DM
    Davis Hugh M.Director, President and COO
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    26.8K sh
    		Dec 2, 2025Dec 4, 2025
    traded Dec 2, 2025
    		+2dSEC FORM 4

    Evidence

    9
    DM
    Davis Hugh M.Director, President and COO
    ACRSAclaris Therapeutics, Inc.
    Option exercise
    		M—
    26.8K sh
    		Dec 2, 2025Dec 4, 2025
    traded Dec 2, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002076327-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 2, 2026
    Published
    Feb 6, 2026
    Ingested by INSIDER
    Nov 5, 04:18 UTC
    Last re-read
    Nov 5, 04:18 UTC

    Extracted facts

    Filer
    Kolbeck Roland Wilhelm
    Role
    Chief Scientific Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Aclaris Therapeutics, Inc. — Restricted Stock Units
    Ticker
    ACRS
    Shares
    95.7K
    Price per share
    $0
    Execution date (reported)
    Feb 2, 2026
    Owned after transaction
    95.7K shares
    Days from execution to publication
    4

    What this establishes

    Kolbeck Roland Wilhelm filed this Form 4 reporting a grant or award of ACRS on Feb 2, 2026. It became public on Feb 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Kolbeck Roland Wilhelmcik:0002076327
    Issuer
    Aclaris Therapeutics, Inc.cik:0001557746

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.